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Abstract
Aims/hypothesis Decreased sleep duration and/or impaired
sleep quality negatively influence glucoregulation. The aim
of this study was to assess subjective sleep characteristics in
patients with type 1 diabetes, to relate sleep characteristics
to long-term glycaemic control and to assess possible risk
factors for impaired sleep.
Methods We studied 99 adult patients with type 1
diabetes (55 men, 44 women, duration of diabetes
26.9±1.2 years) and 99 age-, sex- and BMI-matched
non-diabetic controls. Subjective sleep characteristics
were assessed by validated questionnaires, i.e. Pittsburgh
Sleep Quality Index, Epworth Sleepiness Scale and the
Berlin Questionnaire. Glucoregulation was assessed by
HbA1c values. Clinical variables were obtained from
medical charts. Depression was assessed by the Hospital
Anxiety and Depression Scale (HADS). Peripheral poly-
neuropathy was assessed by neurological examination and
quantitative sensory testing.
Results Of the patients with type 1 diabetes, 35% had
subjective poor sleep quality compared with 20% of the
control participants (p=0.021). A higher proportion of the
patients with type 1 diabetes were at increased risk for
obstructive sleep apnoea (OSA) (17.2% vs 5.1%, p=0.012).
There was no significant association between individual
sleep characteristics and HbA1c values. On logistic regression
analysis, the HADS depression score, presence of peripheral
polyneuropathy, habitual snoring and other sleep disturbances
(e.g. hypoglycaemia) were independently associated with
poor sleep quality.
Conclusions/interpretation Adult patients with long-
standing type 1 diabetes mellitus have disturbed subjec-
tive sleep quality and a higher risk for OSA compared
with control participants. Subjective sleep disturbances
are part of the complex syndrome of long-standing type
1 diabetes.
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Patients with type 2 diabetes report sleep disturbances more
frequently than individuals from the general population [1, 2].
This is relevant for glucoregulation, as epidemiological [3–5]
and experimental studies [6–8] have shown that reduced
sleep duration and/or decreased sleep quality markedly
reduce glucose tolerance and insulin sensitivity.
There are only a few studies on sleep characteristics in
patients with type 1 diabetes.
Jauch-Chara et al. [9] reported a trend towards less slow
wave sleep in 14 non-hypoglycaemic adult patients with
type 1 diabetes. Children with type 1 diabetes had more
disrupted sleep [10, 11] and more sleep disorders [12] than
healthy children. Conversely, in adult patients with type 1
diabetes, partial sleep deprivation, even during only a single
night, reduced peripheral insulin sensitivity by 21% [13].
Subjective sleep characteristics and their relation with
glucoregulation have not been studied in adult patients
with type 1 diabetes.
We hypothesised that adult patients with type 1 diabetes
may have alterations in subjective sleep characteristics,
assessed by validated sleep questionnaires, compared with
healthy controls. In addition, we hypothesised that subjective
sleep disturbances would be associated with impaired
glucoregulation. Therefore, the aim of the present study was:
(1) to assess subjective sleep characteristics by validated sleep
questionnaires in adult patients with type 1 diabetes,
compared with age-, sex- and BMI-matched non-diabetic
controls; (2) to relate sleep characteristics to the quality of
glycaemic control, i.e. HbA1c values; and (3) to assess
possible risk factors for impaired sleep characteristics in
adult patients with type 1 diabetes.
Methods
Participants
We included 99 consecutive patients with type 1 diabetes
mellitus (55 men, 44 women) attending the outpatient clinic
of the Leiden University Medical Center, and 99 age-,
sex- and BMI-matched non-diabetic controls recruited by
advertisement. Every patient with type 1 diabetes was
individually matched with one non-diabetic healthy
control for age, sex and BMI.
Exclusion criteria for both groups were: (1) previously
diagnosed sleep disorders; (2) psychiatric disorders and/or
use of psychotropic medication; (3) pregnancy or lactation;
(4) working in nights shifts in the last 3 months; (5)
travelling across time zones in the previous month; (6) age
<18 years; (7) other endocrine disorders; (8) neuropathy
caused by other conditions than type 1 diabetes; (9) chronic
co-morbidity, other than peripheral neuropathy, associated
with pain; and (10) chronic use of glucocorticoids.
The study was approved by the medical ethical committee
of Leiden University Medical Centre and written informed
consent was obtained from all participants prior to the study.
Study design
Patients and controls were asked to complete three validated
sleep questionnaires—the Pittsburgh Sleep Quality Index
(PSQI), the Epworth Sleepiness Scale (ESS), and the Berlin
Questionnaire (BQ)—that provide data on sleep quality,
daytime sleepiness and the presence of sleeping disorders
[14–16]. An additional questionnaire focused on duration
and insulin management of type 1 diabetes, use of
medication, co-morbidity, current smoking status and use
of alcohol and coffee. Four questions aimed to identify
restless legs syndrome (RLS), using the minimum criteria
defined by the International RLS Study Group [17]. As
depressive feelings may also affect sleep characteristics,
anxiety and depression scores were assessed by the Hospital
Anxiety and Depression scale (HADS) [18].
Sleep disturbances were identified by the answers of the
ten possible encountered sleep disturbances of the PSQI
questionnaire. The option ‘three times or more per week’
was taken as the affirmative answer. Habitual snoring was
defined as a ‘yes’ answer to the three-item question ‘Do
you snore’ in the BQ. The participants who answered ‘not
known’ to this question were classified as non-snorers. We
also included additional questions: ‘Has your sleep been
disturbed by hypoglycaemia in the past month? Has your
sleep been disturbed by hyperglycaemia in the past month?’
The following four options were provided: ‘never’; ‘less
than once per week’; ‘once or twice per week’; and ‘three
times or more per week’.
The following data were obtained from medical
records for the 12 months preceding the current study.
Microvascular complications were defined by the pres-
ence of: (1) retinopathy identified by retinal photography,
detailed ophthalmologic examination and/or previous
laser therapy; or (2) nephropathy identified by increased
urinary albumin-to-creatinine ratios (men >2.5 μg/μmol,
women >3.5 μg/μmol). Macrovascular complications
were defined by objective documentation of coronary
artery disease (diagnostic cardiac exercise test, coronary
angiography, documented myocardial infarction and/or
coronary artery bypass surgery or percutaneous coronary
interventions), cerebral vascular disease (documented
focal neurological findings supported by appropriate
imaging studies) or peripheral vascular disease defined
by reduced ankle–arm index or angiography. Hyperten-
sion was defined as systolic blood pressure ≥135 mmHg
or diastolic blood pressure ≥85 mmHg at multiple
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occasions or treatment with antihypertensive medication.
All patients had HbA1c data obtained within the previous
3 months. An HbA1c value of 7.5% (58 mmol/mol) was
taken as the cut-off point dividing well-controlled vs
moderate-to-poorly controlled patients.
The presence of peripheral polyneuropathy in the lower
extremities was assessed by a single researcher (M. van
Dijk), both in all type 1 diabetes patients and all controls,
using the modified Toronto Clinical Neuropathy scale
(mTCNs, see below) [19] and a neurothesiometer (Scientific
Laboratory Supplies, Nottingham, UK). For the present
study, peripheral polyneuropathy was considered to be
present using a 2.5 percentile cut-off point for abnormality
using data from the matched healthy controls of the present
study, when either mTCNs score was >5 points or the
vibration perception threshold was >18.4 V.
Assessment of subjective sleep characteristics
Pittsburgh Sleep Quality Index The validated PSQI is a
19-item self-rated questionnaire for assessing subjective
sleep quality over the previous month. These questions
generate seven ‘component’ scores, each weighted equally
from 0 to 3: subjective sleep quality; sleep latency; sleep
duration; habitual sleep efficiency; sleep disturbances; use
of sleep medication; and daytime dysfunction. The global
PSQI score ranges from 0 to 21, with higher scores
indicating worse sleep quality.
Epworth Sleepiness Scale The ESS is a validated eight-
item questionnaire, focusing on the likelihood of falling
asleep in several common situations encountered in daily
life on a scale of 0 to 3. Scores range from 0 (the least
sleepy) to 24 (the most sleepy). Scores equal to, or above,
ten are interpreted as hypersomnolence [15].
Berlin Questionnaire The BQ consists of ten questions on
risk factors for sleep apnoea, subdivided into three
symptom categories: (1) snoring and apnoeas (six points);
(2) wake-time sleepiness or fatigue (three points); and (3)
the presence of obesity or hypertension (two points). If two
or more categories are positive (categories 1 and 2: two or
more points; category 3: one or more points), a person is at
high risk of having sleep apnoea [16].
Evaluation of depression
Hospital Anxiety and Depression Scale The HADS consists
of 14 items scoring anxiety and depression. Each item is
measured on a four-point scale. Score for anxiety and
depression subscale range from 0 to 21, and values of the
total score range from 0 to 42. Higher scores indicate more
severe anxiety or depression. A total score of 13 or more
was considered to be increased [18]. This questionnaire was
provided to the participants after the initial study day. Of
the 99 patients, 87 (78.8%) and 80 of the 99 healthy
controls (80.8%) returned the HADS questionnaire. The
other questionnaires were completed by all participating
type 1 diabetic patients and controls.
Assessment of peripheral polyneuropathy
Modified Toronto Clinical Neuropathy Scale The mTCNs
consists of a brief easily administered semi-structured
clinical interview and clinical sensory examination to assess
symptoms and signs of diabetic sensorimotor polyneurop-
athy. The mTCNS rates individual symptoms (foot pain,
numbness, tingling, weakness, imbalance, upper limb
symptoms) as absent or present, and if present, grades
them depending on interference with sense of well-being or
activities of daily living. Symptoms without interference
with sense of well-being or activities of daily living are
graded as 1, those that interfere with sense of well-being,
but not with activities of daily living as 2, and those that
interfere with both as 3. The clinical sensory examination
was performed unilaterally. In the case of previous trauma
the unaffected leg was chosen, and otherwise the choice
of the leg was random. Pinprick, temperature, light
touch, vibration and position sense were graded as: (0)
normal; (1) abnormal at the toes only; (2) between the
toes and the ankle; or (3) or above the ankle [19]. For
each of these modalities, reference stimuli were given to
the dorsal site of one hand, after which testing was carried
out on the sites described before, while individuals kept
their eyes closed.
Neurothesiometer Before testing vibration perception
threshold on the toes, participants were familiarised with
vibration stimuli by applying these to the dorsum of one
hand. Subsequently, vibration stimuli were applied bilaterally
to the distal pulp of both toes. Individuals were instructed to
indicate when vibration was first perceived. Vibration
intensity was gradually increased until vibration was first
detected by the patient or until a maximum output was
reached. Testing was carried out with the individual’s eyes
closed. Testing was carried out twice on each toe, and a mean
of both values was calculated in volts.
Statistical analysis
Data were analysed using PASW Statistics version 17.0.2
(SPSS, Chicago, IL, USA).
Continuous variables were described as mean±SEM;
categorical variables were expressed as proportions. We
used the paired t test and the McNemar test for differences
in means and proportions for continuous and categorical
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paired variables, respectively, and the two-tailed indepen-
dent t test and the χ2 test for unpaired data.
In patients with type 1 diabetes, logistic regression analysis
was performed to examine the association of each sleep
characteristic with poor glycaemic control (yes/no) adjusting
for age, sex, BMI, use of alcohol (>1 glass/day, yes/no), and
anxiety and depression scores according to the HADS.
To investigate variables for impaired sleep quality
(PSQI>5) in the diabetic population, we fitted logistic
regressions separately for all possible variables that could
affect sleep quality: total exogenous insulin dose (units
per kilogram per day), use of beta-blockers (yes/no), use
of ACE inhibitors (yes/no), anxiety and depression score
according to HADS, presence of hypertension (yes/no),
nephropathy (yes/no), peripheral polyneuropathy (yes/no),
macrovascular disease (yes/no), uncomfortable temperatures
(yes/no), pain (yes/no), polyuria (yes/no), other sleep
disturbances (e.g. metabolic dysregulation), habitual snoring
(yes/no), high risk for OSA (yes/no), and RLS (yes/no). In
these analyses, we adjusted for the confounders age, sex and
BMI by including them as covariates. Subsequently, we
performed multivariate logistic regression analysis—
including age, sex, BMI, HbA1c, duration of the diabetes




We included 99 patients with type 1 diabetes and 99 healthy
non-diabetic controls matched for sex (55 men, 44 women),
age (43.9±1.3 vs 44.1±1.3 years) and BMI (24.5±0.3 vs
24.5±0.3 kg/m2). The two groups did not differ with
respect to current smoking status or use of alcohol or
coffee. Clinical characteristics are summarised in Table 1.
Patients with type 1 diabetes used more frequently ACE
inhibitors, calcium antagonists, statins, angiotensin II
receptor antagonists and anti-platelet agents. According to
the HADS, both anxiety (5.0±0.4 vs 3.7±0.3, p=0.004)
and depression scores (3.3±0.4 vs 1.6±0.2, p=0.001) were
significantly higher in the patients with type 1 diabetes.
Thirteen patients (13.1%) had elevated scores for anxiety
and depression (total HADS score 13 or more) vs six
(6.1%) of the controls (p=0.267).The mean duration of
the diabetes was 26.9±1.2 years. HbA1c values were 7.8±
0.1% (62±1.3 mmol/mol). Multiple daily insulin injec-
tions were used by 85 patients and the other 14 patients
used continuous s.c. insulin infusion. The mean insulin
dose was 0.70±0.0 Ukg−1 day−1. Microvascular compli-
cations were present in 36 patients: 24 patients had
retinopathy and 19 patients had nephropathy. The criteria
for peripheral polyneuropathy were met by 45 patients
compared with two of the matched healthy controls
(p=0.000). Peripheral polyneuropathy was considered to
be present, using a 2.5 percentile cut-off point for
abnormality using data from the matched healthy controls
of the present study, when either mTCNs score was >5
points or the vibration perception threshold was >18.4 V.
Macrovascular complications were present in 15 patients.
Subjective sleep characteristics Self-reported mean duration
of sleep in the PSQI did not differ between patients and
controls (7.2±0.1 vs 7.1±0.1 h, p=0.372; Table 2). In
addition, the proportion of short sleepers (<5 h) did not
differ significantly between the two groups (1% vs 1%, p=
1.00), and nor did the proportion of long sleepers (>9 h: 1%
vs 1%, p=1.00). Although there were no significant differ-
ences in global PSQI scores between patients and controls,
35.4% of the patients had a total PSQI score >5, compared
with only 19.2% of the controls, indicating a higher number
of patients with poor sleep quality (p=0.021). In the
individual domains of the PSQI questionnaire, patients more
often reported sleep disturbances (p=0.001) and daytime
dysfunction (p=0.031). The following sleep disturbances
occurred more often in patients than in controls: polyuria
(42.4% vs 24.2%, p=0.004), pain (8.1% vs 0%, p=0.008),
uncomfortable temperatures (8.1% vs 1.0%, p=0.021) and
habitual snoring (51% vs 34%, p=0.010).
The BQ indicated that more patients were at high risk for
obstructive sleep apnoea (OSA) than controls (17.2 vs
5.1%, p=0.012). Despite the reduction in sleep quality and
more sleep disorders, there were no significant differences
in reported daytime sleepiness between the two groups.
Daytime hypersomnolence affected 19.2% of the patients
vs 11.1% of the controls (p=0.152).
Seventy-five patients answered the questions: ‘Has your
sleep been disturbed by hypoglycaemia in the past month?
Has your sleep been disturbed by hyperglycaemia in the
past month?’ Forty-one patients indicated that their sleep
was disturbed by hypoglycaemia in the past month: 34
patients indicated that their sleep was disturbed less than
once per week, and seven patients indicated impaired sleep
by hypoglycaemia one to two times per week. Disturbed
sleep due to hyperglycaemia was reported by 28 patients
with type 1 diabetes: 24 patients indicated disturbed sleep
less than once per week, two patients one to two times per
week, and two patients reported a disturbed sleep by
hyperglycaemia more than three times per week.
Well-controlled vs moderate-to-poorly controlled patients
Type 1 diabetes patients were divided in two groups: well
controlled (HbA1c<7.5% [<58 mmol/mol], n=51) vs
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moderate to poorly controlled (HbA1c≥7.5% [≥58 mmol/mol],
n=48). There were no significant differences in clinical
characteristics between both groups. We found no
significant differences between both groups in subjective
sleep characteristics, i.e. self-reported sleep duration,
sleep quality, daytime sleepiness, or the prevalence of
Patients with type 1 diabetes
(n=99)
Controls (n=99) p value
Sex
Male/female 55/44 55/44 1.000
Age (years) 43.9±1.3 44.1±1.3 0.472
BMI (kg/m2) 24.5±0.3 24.5±0.3 0.986




HbA1c ≥ 7.5% (≥58 mmol/mol) 48 (48.5)
Duration of diabetes (years) 26.9±1.2 NA
Mean insulin dose (U kg−1 day−1) 0.7±0.0 NA
Medications, n (%)
Insulin NA
Continuous s.c. insulin infusion 14 (14.0)
Insulin injections 86 (86.0)
Beta-blockers 6 (6.1) 4 (4.0) 0.754
ACE inhibitors 29 (29.3) 5 (5.1) 0.000
Calcium antagonists 9 (9.1) 2 (2.0) 0.039
Statins 39 (39.4) 6 (6.1) 0.000
Oral glucose-lowering agents 1 (1.0) 0 1.000
Angiotensin II receptor antagonists 9 (9.1) 1 (1.0) 0.021
Diuretics 8 (8.1) 3 (3.0) 0.227
Oral contraceptives 7 (7.1) 8(8.1) 1.000
Anti-platelet agents 17 (17.2) 2 (2.0) 0.000
Proton pump inhibitors 6 (6.1) 2 (2.0) 0.289
Benzodiazepines 0 0
Other 24 (24.2) 18 (18.2) 0.391
Diabetic complications, n (%) NA
Microvascular 36 (36.4)
Retinopathy 24 (24.2)
Laser treatment 18 (18.2)
Nephropathy 19 (19.2)
Macrovascular 15 (15.0)
Peripheral polyneuropathy 45 (45.5) 2 (2.0) 0.000
mTCNs score 5.6±0.5 1.4±0.2 0.000
Neurothesiometer (V) 11.5±0.9 6.8±0.4 0.000
Hypertension, n (%) 24 (22.0)
Current cigarette smokers, n (%) 18 (18.0) 11 (11.0) 0.210
Alcohol consumption ≥1 glass/day, n (%) 41 (41.4) 36 (36.4) 0.551
Coffee consumption ≥1 cup/day, n (%) 75 (75.8) 79(79.8) 0.307
HADS
Anxiety score 5.0±0.4 3.7±0.3 0.004
Depression score 3.3±0.4 1.6±0.2 0.001
Total score 8.3±0.7 5.3±0.5 0.002
Score≥13 13 (13.1) 6 (6.1) 0.388
Table 1 Clinical characteristics
of the patients with type 1
diabetes and their non-diabetic
matched controls
Data are mean±SEM for contin-
uous variables and n (%) for
categorical variables
NA, not applicable
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sleep disorders (data not shown). Logistic regression
analysis was performed to assess the association between
self-reported sleep characteristics and high HbA1c values
(≥7.5% [≥58 mmol/mol]). There were no significant
associations between individual sleep characteristics and
impaired glycaemic control (Table 3).
Assessment of risk factors of impaired sleep quality
(PSQI>5) in patients with type 1 diabetes
Logistic regression analyses for all possible variables that
could affect sleep quality in patients with type 1 diabetes
showed significant associations between impaired sleep
quality and the presence of peripheral polyneuropathy
(OR 2.98, 95% CI 1.05–8.46, p=0.040), habitual snoring
(OR 4.19, 95% CI 1.47–11.97, p=0.007), uncomfortable
temperatures (OR 7.89, 95% CI 1.31–47.31, p=0.024),
other sleep disturbances, e.g. metabolic dysregulation (OR
9.52, 95% CI 1.03–88.17, p=0.047), HADS anxiety score
(OR 1.20, 95% CI 1.02–1.40, p=0.026), and HADS
depression score (OR 1.30, 95% CI 1.07–1.58, p=0.009;
Table 4).
Multivariate logistic regression, including age, sex, BMI,
HbA1c, duration of diabetes and the risk factors, that
showed a p value <0.2 in the preceding separate analyses
confirmed that habitual snoring (OR 9.95, 95% CI 1.76–
Sleep characteristic Patients with type 1 diabetes (n=99) Controls (n=99) p value
Sleep duration
Self-reported sleep duration (h) 7.2±0.1 7.1±0.1 0.372
Sleep quality
PSQI
Global score 4.6±0.3 4.0±0.2 0.079
PSQI >5, n (%) 36 (35.4) 20 (19.8) 0.021
Component score
1. Subjective sleep quality 0.88±0.1 0.73±0.1 0.096
2. Sleep latency 0.68±0.1 0.74±0.1 0.598
3. Sleep duration 0.73±0.1 0.77±0.1 0.781
4. Sleep efficiency 0.31±0.1 0.22±0.1 0.307
5. Sleep disturbances 1.12±0.0 0.92±0.0 0.002
6. Sleeping medication 0.13±0.0 0.06±0.0 0.239
7. Daytime dysfunction 0.75±0.1 0.52±0.1 0.031
Daytime sleepiness
ESS
Total score 5.9±0.4 5.1±0.4 0.192
Score≥10, n (%) 19 (19.2) 11 (11.1) 0.152
Sleep disorders, n (%)
BQ
Habitual snoring 51 (51.0) 34 (34.0) 0.010
High-risk OSA 17 (17.2) 5 (5.1) 0.012
RLS 9 (9.3) 10 (10.1) 1.000
Table 2 Subjective sleep
characteristics of the patients
with type 1 diabetes vs matched
non-diabetic controls
Data are mean±SEM for
continuous variables and n (%)
for categorical variables
Table 3 Results of logistic regression analysis of the association
between sleep characteristics and impaired glucoregulation in 99
patients with type 1 diabetes
Sleep characteristic HbA1c ≥7.5% (≥58 mmol/mol)
OR (95% CI) p value
Sleep durationa
Self-reported sleep duration (h) 0.77 (0.48–1.24) 0.287
Sleep qualitya
PSQI
Global PSQI score 1.06 (0.89–1.27) 0.532
PSQI >5 1.31 (0.47–3.63) 0.602
Daytime sleepinessa
ESS
Total ESS-score 1.04 (0.92–1.18) 0.521
ESS≥10 2.82 (0.84–9.42) 0.093
Sleep disorders
BQ
Habitual snoring 1.24 (0.51–3.01) 0.639
High-risk OSA 0.50 (0.15–1.59) 0.238
RLS 2.59 (0.59–11.41) 0.209
Each sleep characteristic was adjusted for age, sex, BMI and alcohol
consumption (>1 glass/day)
aAlso adjusted for HADS
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56.14, p=0.009), HADS depression score (OR 1.42, 95%
CI 1.00–2.02, p=0.048), presence of peripheral polyneuro-
pathy (OR 7.45, 95% CI 1.08–51.20, p=0.041) and other
sleep disturbances (e.g. metabolic dysregulation [OR 27.78,
95% CI 1.11–697.48, p=0.043]) were still independent risk
factors for poor sleep in the type 1 diabetes patients. Peripheral
polyneuropathy, clinically assessed according to strict criteria,
was an independent risk factor for impaired sleep, even after
adjusting for ‘pain’ and ‘uncomfortable temperatures’.
Discussion
The aim of this study was to assess subjective sleep
characteristics in adult patients with long-standing type 1
diabetes, and to relate sleep variables to HbA1c values.
Although sleep duration did not differ between patients and
controls, more patients had poor sleep quality compared
with non-diabetic, age-, sex- and BMI-matched controls.
Patients with type 1 diabetes reported more sleep disturbances
and daytime dysfunction. A higher proportion of the patients
with type 1 diabetes were at increased risk for OSA. There
was no association between subjective sleep characteristics
and impaired glucoregulation. These observations indicate
that type 1 diabetes is associated with an increased prevalence
of disturbed subjective sleep characteristics, which do not
relate to glucoregulation.
Previous studies on the relation between diabetes and sleep
characteristics mainly focussed on patients with type 2
diabetes [1, 2]. Only a few studies have assessed sleep
characteristics in patients with type 1 diabetes [9–12]. Those
studies investigated relatively few individuals and children
[10–12] with type 1 diabetes. The present study extends
those observations in showing that in a large group of adult
patients with a long history of type 1 diabetes subjective
sleep characteristics are impaired, compared with a carefully
matched control group, controlling for potential confounding
factors such as age, sex and BMI.
This decrease in sleep quality and increased prevalence
of sleep disturbances in patients with long-standing type 1
diabetes may have important implications, as previous
studies showed that reduction of sleep duration and/or
Table 4 Results of logistic regression: possible risk factors for impaired sleep quality (PSQI >5) in 99 patients with type 1 diabetes
Characteristic Poor sleep quality (PSQI >5)
Minimally adjusted model
(adjusted for age, sex and BMI)
Maximally adjusted model
OR (95% CI) p value OR (95% CI) p value
Clinical characteristics
Use of medication
Total insulin dose (U kg−1 day−1) 1.32 (0.21–8.31) 0.768 NI
Use of beta-blockers 1.00 (0.17–5.92) 0.996 NI
Use of ACE inhibitors 0.42 (0.14–1.25) 0.118 0.85 (0.14–5.11) 0.859
Anxiety and depressive symptoms
HADS anxiety score 1.20 (1.02–1.40) 0.026 0.91 (0.66–1.26) 0.572
HADS depression score 1.30 (1.07–1.58) 0.009 1.42 (1.00–2.02) 0.048
Diabetic complications
Hypertension 0.41 (0.13–1.31) 0.133 0.38 (0.06–2.32) 0.292
Presence of nephropathy 0.88 (0.29–2.68) 0.828 NI
Macrovascular disease 0.78 (0.21–2.92) 0.707 NI
Presence of peripheral neuropathy 3.0 (1.05–8.46) 0.040 7.45 (1.08–51.20) 0.041
Sleep disturbances
Uncomfortable temperatures 7.89 (1.31–47.31) 0.024 4.30 (0.27–69.45)
Presence of pain 3.38 (0.72–15.84) 0.122 6.50 (0.50–84.43) 0.152
Polyuria 1.49 (0.20–3.97) 0.405 NI
Other sleep disturbances, (e.g. metabolic dysregulation) 9.52 (1.03–88.17) 0.047 27.78 (1.11–697.48) 0.043
Sleep disorders
Habitual snoring 4.20 (1.47–11.97) 0.007 9.95 (1.76–56.14) 0.009
High-risk OSA 1.27 (0.40–4.05) 0.682 NI
RLS 0.89 (0.20–3.97) 0.883 NI
NI, not included in final model because p>0.2
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decreased sleep quality impair glucose tolerance and reduce
insulin sensitivity in healthy controls [6–8]. Sleep
disturbances might have a similar negative effect on
glucose metabolism in patients with type 1 diabetes,
resulting in worse diabetic control. However, this presumed
relationship between sleep disturbances and impaired
glucose metabolism, assessed by HbA1c values, was not
detectable in the current study. Nonetheless, it is still
possible that disturbed sleep characteristics influence
glucose metabolism in these patients. However, the effects
of impaired sleep characteristics may not simply be
reflected in HbA1c values because intensive glucose control
and frequent, appropriate adjustments of insulin doses in
patients at risk might have obtunded the effects of impaired
sleep characteristics on glucoregulation.
Various aspects of diabetes could be linked to disturbed
sleep quality, including physical complications of the
disease, psychological factors, metabolic fluctuations and
high prevalence of sleep disorders. In the patients with
type 1 diabetes in our study, disturbed sleep quality was
independently associated with habitual snoring, higher
depression scores according to the HADS questionnaire,
presence of polyneuropathy and other sleep disturbances,
mainly by hypoglycaemia.
Previous studies showed a high prevalence of depression
in diabetes [20] and chronic pain conditions [21]. Although
we excluded patients with a known depression, use of
psychotropic drugs, and co-morbid disorders (other than
neuropathy) associated with pain, in our study higher
depression scores were independently associated with
impaired sleep quality.
Many patients with type 1 diabetes in our study used
ACE inhibitors, statins and/or beta-blockers, which might
interfere with sleep characteristics. The effects of beta-
blockers on sleep are not equivocal. A previous study
showed that the use of beta-blockers could positively or
negatively affect sleep [22]. A case report by Cicolin et al.
suggested that ACE inhibitors may contribute to OSA by
inducing upper airway inflammation [23]. Therefore, we
have considered that the use of beta-blockers and/or ACE
inhibitors might affect sleep quality in patients with type 1
diabetes. However, in univariate logistic regression analysis
we did not find an association between the use of beta-
blockers or ACE inhibitors and impaired sleep quality. In
univariate logistic regression analysis there was an associ-
ation between the use of ACE inhibitors and high risk of
OSA. However, this association was no longer significant
after correction for the confounders age, sex, BMI and
hypertension. There are conflicting data on sleep distur-
bances in patients treated with statins. Some studies
reported higher prevalence of sleep disturbances in patients
treated with lipophilic statins than with pravastatin [24, 25]
whereas other studies did not find an increased prevalence
of sleep disturbances in patients treated with different
statins compared with placebo [26, 27]. In the present
study, there was no difference in the use of statins between
patients with a poor sleep quality (PSQI>5) and patients
with a good sleep quality (PSQI≤5). The use of statins was
even higher in the group with good sleep quality. In
accordance, in univariate analysis, use of statins was not
associated with impaired sleep quality. Therefore, our
conclusions are not likely to be merely explained by the
use of medications in our patients.
The clinical assessment of peripheral polyneuropathy
according to strict criteria in individuals with type 1
diabetes is a major strength of our study, as our study
shows diabetic polyneuropathy was a major determinant
of impaired sleep. Polyneuropathy contributes to im-
paired sleep via several potential mechanisms. First,
neuropathic pain may lead to disturbed sleep [28].
Second, polyneuropathy can impair thermoregulation. It
has been proposed that autonomic changes in skin
temperature modulate the neuronal activity of the thermo-
sensitive neurons in the pre-optic area/anterior hypothal-
amus, which, in turn, regulate vigilance and sleepiness
[29]. This hypothesis is supported by a report showing that
diabetic patients, even those without evidence of clinical
neuropathy, show impaired thermoregulation during sleep
[30].
The relatively high prevalence of type 1 diabetic
patients with a high risk for OSA, according to the BQ,
suggests the potential of a high burden of unrecognised
OSA in people with type 1 diabetes. This is a relatively
new finding, in accordance with a recent pilot study of
Borel et al., which observed a prevalence of OSA of
40% in 37 non-obese adult patients with type 1 diabetes
[31]. In accordance with our data, this observation is
remarkable, as the BMI, which is a risk factor for OSA in
the general population, of our patients with type 1 diabetes
was matched to that of the healthy controls. Several
studies in patients with type 2 diabetes have shown that
OSA is associated with the presence of autonomic
neuropathy [32, 33], which might also be involved in
patients with type 1 diabetes. Unfortunately, our current
study was not designed to elucidate underlying mecha-
nisms of disturbed sleep, and we did not include assess-
ments of autonomic neuropathy. Nonetheless, there was no
association between poor glycaemic control (HbA1c≥
7.5%) and a ‘high’ risk for OSA in our study, despite the
association between sleep-disordered breathing, glucose
intolerance and insulin resistance in patients with type 2
diabetes [34, 35]. There was also no association between
the occurrence of hypoglycaemia and the risk for OSA in
our patients [36].
Sleep characteristics were assessed by validated
questionnaires in the present study. The PSQI and ESS
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have been developed to measure sleep quality and
daytime sleepiness, respectively [14, 15], and reflect
stable measures of sleep quality and sleepiness over the
past year [37]. The PSQI has a diagnostic sensitivity of
89.6% and a specificity of 86.5% for identifying cases
with poor sleep quality, using a cut-off score of 5. This
questionnaire has been validated by polysomnographic
measurements [38].The BQ is a screening tool widely
used to differentiate between ‘high-’ and ‘low-risk’
groups for OSA. This risk grouping was useful in the
prediction of respiratory disturbances in consecutive
participants, who visited internists for any reason. For
example, being in the ‘high-risk’ group defined by the BQ
predicted more than five respiratory events per hour with
a sensitivity of 86%, and a specificity of 77% [16]. In
view of the current data, polysomnography is required to
objectively assess the sleep quality and OSA in patients
with type 1 diabetes mellitus at high risk for OSA
according to the BQ.
The current cross-sectional study was designed to assess
subjective sleep variables in patients with type 1 diabetes
mellitus and, therefore, we cannot elucidate from the data
which chain(s) of events lead from type 1 diabetes to
disturbed sleep. In particular, the links between peripheral
polyneuropathy and disturbed sleep and between type 1
diabetes and the risk of OSA are not fully clear. Another
matter is whether disturbed sleep leads to further
impairment of glucose metabolism, with the effect that
sleep disturbances and glycaemic control can interact in a
vicious circle. Additional studies with objective sleep
measurements are warranted to assess these relations in
more detail.
In conclusion, the present study demonstrated that
adult patients with long-standing type 1 diabetes mellitus
have altered self-reported sleep characteristics compared
with sex-, age- and BMI-matched non-diabetic controls.
Therefore, disturbed subjective sleep characteristics are
part of the complex syndrome of long-standing type 1
diabetes mellitus.
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